Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-072470
Filing Date
2022-06-17
Accepted
2022-06-17 17:20:38
Documents
5
Period of Report
2022-08-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2217544-2_def14a.htm DEF 14A 658714
2 GRAPHIC lg_vynethera-4c.jpg GRAPHIC 58250
3 GRAPHIC sg_daviddomzalskinew-bw.jpg GRAPHIC 8221
4 GRAPHIC tm2217544d2-px_pg1vynethebw.jpg GRAPHIC 574585
5 GRAPHIC tm2217544d2-px_pg2vynethe4c.jpg GRAPHIC 374066
  Complete submission text file 0001104659-22-072470.txt   2058449
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38356 | Film No.: 221025109
SIC: 2834 Pharmaceutical Preparations